Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5702356 | Surgical Oncology | 2017 | 8 Pages |
Abstract
Data from a large nationwide oncology database and review of the existing literature do not support adjuvant chemotherapy regimens following curative-intent resection of RPS, even in subgroups at high risk of failure (e.g., R1/R2 resection, high-grade or large tumors). The possible benefit of conventional adjuvant regimens in spindle cell, giant cell, and synovial sarcoma should be explored in prospective studies.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Jashodeep Datta, Brett L. Ecker, Madalyn G. Neuwirth, Rula C. Geha, Douglas L. Fraker, Robert E. Roses, Giorgos C. Karakousis,